GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
Publishing timestamp: 2024-01-31 11:38:47
Summary
GlaxoSmithKline has raised its long-term outlook after the successful launch of its RSV vaccine, Arexvy, which generated $1.5 billion in sales within six months. The launch of RSV vaccines by GSK and Pfizer has been beneficial for both companies, although Pfizer saw fewer sales. GSK now expects to generate over $38 billion in sales by 2031, up from a previous forecast of $33 billion. The company's RSV vaccine is approved for use in adults aged 60 and older, with plans to expand approval for ages 50 to 59. GSK is also planning for at least 12 major product launches in the next four years.
Sentiment: POSITIVE
Tickers: MRNA, GSK-GB, GSK, PFE,
Keywords: health care industry, business, biotech and pharmaceuticals, gsk plc, earnings, biotechnology, moderna inc, business news, pfizer inc, pharmaceuticals,
Source: https://www.cnbc.com/2024/01/31/gsk-posts-blowout-rsv-vaccine-sales-raises-outlook.html